Market Research

In a pivotal achievement for mental health and cannabis research, the Multidisciplinary Association for Psychedelic Studies (MAPS) has overcome substantial regulatory barriers to advance its Phase 2 clinical trial, known as MJP2. This groundbreaking study examines the effects of smoked and vaporized cannabis on post-traumatic stress disorder (PTSD). After years of rigorous advocacy, scientific preparation,…

And why everyone should go to this conference in 2025. I walked into the Palm Beach County Convention Center on November 1st bursting with curiosity. The health and wellness conference I was there to take part in, called The Eudēmonia Summit, was the first of its kind. It was a name I hadn’t heard before…

Colorado’s progressive step toward legalizing psilocybin, primarily for therapeutic purposes, has opened new doors for individuals seeking alternative mental health treatments. As of 2023, residents can apply for access to licensed psilocybin therapy sessions under regulated conditions, providing a safe environment for therapeutic and controlled use. This landmark move is a part of Proposition 122,…

Compass Pathways (NASDAQ: CMPS) has announced plans to reduce its workforce by approximately 30% and halt early-stage research programs, as the company intensifies its focus on the late-stage development of its lead candidate, the COMP360 psilocybin therapy. The London-based mental health company revealed its restructuring strategy alongside its third-quarter financial results, which highlighted an increased…